Discover the most talked about and latest scientific content & concepts.

HL Kaufman, T Amatruda, T Reid, R Gonzalez, J Glaspy, E Whitman, K Harrington, J Nemunaitis, A Zloza, M Wolf and NN Senzer
We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma in a phase II clinical trial. The response of individual lesions, however, was not reported. Since talimogene laherparepvec is thought to mediate anti-tumor activity through both direct tumor cytolysis and induction of systemic tumor-specific immunity, we sought to determine the independent response rate in virus-injected and non-injected lesions.
comments powered by Disqus

* Data courtesy of